Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02314117
Title A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Eli Lilly and Company
Indications

gastroesophageal junction adenocarcinoma

stomach cancer

Therapies

Capecitabine

Fluorouracil

Cisplatin

Ramucirumab

Age Groups: adult
Covered Countries USA | CAN


No variant requirements are available.